Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) – Research analysts at Erste Group Bank raised their FY2027 EPS estimates for Thermo Fisher Scientific in a report released on Wednesday, October 21st. Erste Group Bank analyst H. Engel now expects that the medical research company will post earnings per share of $27.58 for the year, up from their previous forecast of $27.51. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $25.16 per share.
Other equities analysts also recently issued research reports about the stock. BMO Capital Markets downgraded shares of Thermo Fisher Scientific to a “market perform” rating in a research report on Wednesday, September 9th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. CLSA began coverage on shares of Thermo Fisher Scientific in a research report on Thursday, September 3rd. They issued an “outperform” rating and a C$748.00 price objective for the company. Scotiabank initiated coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They set an “outperform” rating for the company. Finally, Morgan Stanley upped their price objective on Thermo Fisher Scientific from $650.00 to $730.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $675.52.
View Our Latest Stock Report on TMO
Thermo Fisher Scientific Stock Performance
NYSE TMO opened at $676.09 on Friday. Thermo Fisher Scientific has a 52-week low of $435.27 and a 52-week high of $705.78. The business’s 50-day moving average price is $644.01 and its 200 day moving average price is $553.96. The company has a quick ratio of 1.18, a current ratio of 1.81 and a debt-to-equity ratio of 0.71. The firm has a market cap of $249.98 billion, a P/E ratio of 36.37, a P/E/G ratio of 2.89 and a beta of 0.87.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $0.28. The firm had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the company posted $5.79 earnings per share.
Hedge Funds Weigh In On Thermo Fisher Scientific
Several institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Thermo Fisher Scientific in the second quarter worth approximately $15,501,867,000. Corient Private Wealth LP purchased a new position in Thermo Fisher Scientific during the second quarter worth approximately $382,547,000. Bank of New York Mellon Corp purchased a new position in Thermo Fisher Scientific during the second quarter worth approximately $1,974,561,000. Bank of America Corp DE acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Thermo Fisher Scientific by 0.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock valued at $1,239,625,000 after purchasing an additional 22,827 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Thermo Fisher Scientific
In related news, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael D. Shafer sold 25,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. The trade was a 54.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,768 shares of company stock worth $44,122,820 over the last ninety days. 0.33% of the stock is currently owned by corporate insiders.
Key Thermo Fisher Scientific News
Here are the key news stories impacting Thermo Fisher Scientific this week:
- Positive Sentiment: Q3 beat and stronger outlook: Thermo Fisher reported third-quarter revenue of $12.14 billion, up 9.1% year over year, while adjusted EPS of $6.68 exceeded the $6.40 consensus estimate. Organic growth reached 6%, margins improved, and management raised its full-year 2026 revenue-growth and earnings outlook. Thermo Fisher Scientific Reports Third Quarter 2026 Results
- Positive Sentiment: Analysts remain bullish: TD Cowen raised its price target to $810 and retained a “buy” rating. Stifel Nicolaus lifted its target to $775, while Robert W. Baird raised its target to $756 and maintained an “outperform” rating. The revisions reflect confidence in recovery across clinical research, bioproduction and laboratory products.
- Positive Sentiment: Industry growth supports long-term demand: Research indicates the peptide-synthesis market could expand from $0.98 billion in 2026 to $1.54 billion by 2031, aided by GLP-1 drug development. Thermo Fisher is among the companies positioned to benefit from increased pharmaceutical and research activity. Global Peptide Synthesis Market Forecast
- Neutral Sentiment: Peer comparison: A new survey compares Thermo Fisher with Twist Bioscience, but it does not provide a clear new company-specific catalyst for TMO. Twist Bioscience versus Thermo Fisher Scientific
- Negative Sentiment: Options activity signals caution: Heavy put-option buying, including activity roughly 52% above average, suggests some traders are hedging against a pullback or positioning defensively after the earnings release. Thermo Fisher Scientific Stock Sees Heavy Put Option Buying
- Negative Sentiment: Muted earnings reaction and valuation risk: The strong report has not produced a sustained rally, potentially because TMO trades near its 12-month high at a forward-looking premium valuation. Investors may be demanding clearer evidence that the end-market recovery can justify the stock’s elevated earnings multiple.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.
Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.
Featured Stories
- Five stocks we like better than Thermo Fisher Scientific
- Microsoft’s Earnings Problem: Even Great May Not Be Enough
- 3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
